Skip to main content
Fig. 4 | Stem Cell Research & Therapy

Fig. 4

From: Extracellular vesicle mimics made from iPS cell-derived mesenchymal stem cells improve the treatment of metastatic prostate cancer

Fig. 4

Biodistribution of systemically infused NVs in mice carrying bone metastatic PC3 cancer. Nude mice carrying Luc2-PC3 tumor in the right hind leg were IP infused with 1 × 1010 p/g DiR-liposomes or DiR-NVs (af), or rLuc-NVs (gi). a, b The representative in vivo imaging of Luc2 and DiR signals at 3, 12, and 24 h after infusion. c The relative intensities of in vivo DiR signals in Luc2+ tumor region and non-tumor regions were quantified as percentages of total DiR intensities at 3, 12, 24, and 48 h after infusion. df Tumor-carrying legs (T) and organs were collected 12 h after infusion of DiR-liposomes or DiR-NVs for ex vivo imaging and consequent quantification. H, heart; Ln, lungs; Lv, liver; S, spleen; K, kidneys; GI, gastrointestinal tract; P, pancreas. g In vivo imaging of rLuc signals at 3, 12, and 24 h after IP infusion of rLuc-NVs. h Absolute intensities of rLuc signals in tumor and non-tumor regions. i The percentages of tumor rLuc signals vs. total rLuc signals at corresponding time points (green dashed line) and vs. total rLuc signals at 3 h (blue solid line). N = 4, *p < 0.05 vs. the liposome group

Back to article page